ArticleNPJ precision oncology2026

The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.

Mai Nagasaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.